vs
GRAFTECH INTERNATIONAL LTD（EAF）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是GRAFTECH INTERNATIONAL LTD的1.8倍（$207.3M vs $116.5M），GRAFTECH INTERNATIONAL LTD净利率更高（-55.9% vs -62.0%，领先6.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -13.2%），GRAFTECH INTERNATIONAL LTD自由现金流更多（$-39.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -7.7%）
格瑞泰克国际有限公司是石墨电极与石油焦生产商，其产品是电弧炉炼钢及其他金属生产的核心原材料。公司总部位于俄亥俄州布鲁克林海茨，在法国加来、西班牙潘普洛纳、墨西哥蒙特雷以及美国宾夕法尼亚州圣玛丽斯均设有生产基地。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EAF vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $116.5M | $207.3M |
| 净利润 | $-65.1M | $-128.6M |
| 毛利率 | -20.9% | — |
| 营业利润率 | -33.6% | -54.7% |
| 净利率 | -55.9% | -62.0% |
| 营收同比 | -13.2% | 25.9% |
| 净利润同比 | -31.6% | 3.5% |
| 每股收益（稀释后） | $-6.86 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $116.5M | $207.3M | ||
| Q3 25 | $144.0M | $159.9M | ||
| Q2 25 | $131.8M | $166.5M | ||
| Q1 25 | $111.8M | $139.3M | ||
| Q4 24 | $134.2M | $164.6M | ||
| Q3 24 | $130.7M | $139.5M | ||
| Q2 24 | $137.3M | $147.0M | ||
| Q1 24 | $136.6M | $108.8M |
| Q4 25 | $-65.1M | $-128.6M | ||
| Q3 25 | $-28.5M | $-180.4M | ||
| Q2 25 | $-86.9M | $-115.0M | ||
| Q1 25 | $-39.4M | $-151.1M | ||
| Q4 24 | $-49.5M | $-133.2M | ||
| Q3 24 | $-36.1M | $-133.5M | ||
| Q2 24 | $-14.8M | $-131.6M | ||
| Q1 24 | $-30.9M | $-170.7M |
| Q4 25 | -20.9% | — | ||
| Q3 25 | 7.2% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | -1.5% | — | ||
| Q4 24 | -7.8% | — | ||
| Q3 24 | -9.2% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | -1.0% | — |
| Q4 25 | -33.6% | -54.7% | ||
| Q3 25 | -3.6% | -106.9% | ||
| Q2 25 | -11.0% | -64.8% | ||
| Q1 25 | -16.3% | -102.6% | ||
| Q4 24 | -18.6% | -74.3% | ||
| Q3 24 | -20.1% | -94.6% | ||
| Q2 24 | -2.0% | -79.1% | ||
| Q1 24 | -15.6% | -151.9% |
| Q4 25 | -55.9% | -62.0% | ||
| Q3 25 | -19.8% | -112.8% | ||
| Q2 25 | -65.9% | -69.0% | ||
| Q1 25 | -35.2% | -108.5% | ||
| Q4 24 | -36.9% | -80.9% | ||
| Q3 24 | -27.6% | -95.7% | ||
| Q2 24 | -10.7% | -89.5% | ||
| Q1 24 | -22.6% | -156.8% |
| Q4 25 | $-6.86 | $-1.28 | ||
| Q3 25 | $-1.10 | $-1.81 | ||
| Q2 25 | $-0.34 | $-1.17 | ||
| Q1 25 | $-0.15 | $-1.57 | ||
| Q4 24 | $-3.51 | $-1.34 | ||
| Q3 24 | $-1.40 | $-1.40 | ||
| Q2 24 | $-0.06 | $-1.52 | ||
| Q1 24 | $-0.12 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | $1.1B | — |
| 股东权益账面价值 | $-259.6M | $-80.0M |
| 总资产 | $1.0B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | $120.7M | $480.7M | ||
| Q1 24 | $165.2M | $112.3M |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $929.5M | — | ||
| Q2 24 | $928.2M | — | ||
| Q1 24 | $926.9M | — |
| Q4 25 | $-259.6M | $-80.0M | ||
| Q3 25 | $-194.4M | $9.2M | ||
| Q2 25 | $-168.4M | $151.3M | ||
| Q1 25 | $-105.3M | $144.2M | ||
| Q4 24 | $-78.9M | $255.0M | ||
| Q3 24 | $-9.0M | $346.8M | ||
| Q2 24 | $16.2M | $432.4M | ||
| Q1 24 | $37.6M | $140.3M |
| Q4 25 | $1.0B | $1.5B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.2B | $1.6B | ||
| Q1 24 | $1.2B | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 57.16× | — | ||
| Q1 24 | 24.64× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-20.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-39.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | -33.7% | -48.6% |
| 资本支出强度资本支出/营收 | 15.8% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-120.5M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-20.9M | $-99.8M | ||
| Q3 25 | $24.7M | $-91.4M | ||
| Q2 25 | $-53.2M | $-108.3M | ||
| Q1 25 | $-32.2M | $-166.5M | ||
| Q4 24 | $-26.4M | $-79.3M | ||
| Q3 24 | $23.7M | $-67.0M | ||
| Q2 24 | $-36.9M | $-77.0M | ||
| Q1 24 | $-530.0K | $-190.7M |
| Q4 25 | $-39.3M | $-100.8M | ||
| Q3 25 | $18.4M | $-92.7M | ||
| Q2 25 | $-57.1M | $-110.7M | ||
| Q1 25 | $-42.5M | $-167.8M | ||
| Q4 24 | $-39.2M | $-79.5M | ||
| Q3 24 | $19.7M | $-68.6M | ||
| Q2 24 | $-43.8M | $-79.0M | ||
| Q1 24 | $-11.0M | $-193.9M |
| Q4 25 | -33.7% | -48.6% | ||
| Q3 25 | 12.8% | -58.0% | ||
| Q2 25 | -43.3% | -66.5% | ||
| Q1 25 | -38.0% | -120.5% | ||
| Q4 24 | -29.2% | -48.3% | ||
| Q3 24 | 15.1% | -49.2% | ||
| Q2 24 | -31.9% | -53.7% | ||
| Q1 24 | -8.1% | -178.2% |
| Q4 25 | 15.8% | 0.5% | ||
| Q3 25 | 4.4% | 0.8% | ||
| Q2 25 | 3.0% | 1.5% | ||
| Q1 25 | 9.2% | 1.0% | ||
| Q4 24 | 9.5% | 0.1% | ||
| Q3 24 | 3.1% | 1.2% | ||
| Q2 24 | 5.1% | 1.4% | ||
| Q1 24 | 7.7% | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EAF
| Graphite Electrodes | $107.0M | 92% |
| By Products And Other | $9.4M | 8% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
